States’ efforts show drug cost isn't biggest obstacle to eliminating hep C; why health care needs a Black Friday sale

Experts assumed the biggest obstacle to eliminating hep C was the sky-high cost of a cure. A STAT investigation reveals more intractable issues. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn't been the biggest problem By Nicholas Florko Experts assumed the biggest obstacle to eliminating hep C was the sky-high cost of a cure. An investigation reveals more intractable issues. Read More Opinion: Health care needs a Black Friday sale: the case for legalizing discounts on medical services By Stacy Bratcher Adobe Eliminating the legal ban on patient discounts would empower health care providers and consumers to drive down costs. Read More STAT+: Akero treatment for NASH reduces liver scarring, achieves goals of mid-stage study By Adam Feuerstein Adobe Akero reported encouraging results for its drug aimed at ameliorating the effects of NASH, which can lead to liver cancer and transplantation. Read More Sponsor content by NOVAVAX How is Novavax taking a global approach to immunization? Novavax is a biotechnology company solely devoted to innovating vaccine technology and setting the world up for success in immunization. Investigational vaccines built on the Novavax platform can be efficiently produced and scaled to meet global demand. Learn more. Opinion: Vaccine guarantees can help prevent the resurgence of polio By Awi Federgruen Ezra Acayan/Getty Images One way to avoid the looming shortfall of polio vaccines: Create an advance market commitment that will guarantee manufacturers of purchases. Read More Tuesday, September 13, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser